-
-
Once the diagnosis of alcohol withdrawal syndrome is confirmed, the treatment of the life-threatening sequelae must be swift. For many years, the pharmacologic agent of choice to treat AWS has been quite controversial. Benzodiazepines, antiepileptic agents, ethanol, and barbiturates have all been the preferred drug at one time or another. In recent years, benzodiazepines have come to the forefront as the drug class of choice, although some agents may offer advantages over others. Several guidelines have been developed to aid the emergency medicine practitioner select the most effective and efficient therapy. This review outlines, in systematic detail, the full range of AWS and risk-directed interventions shown to improve clinical outcomes in AWS.
-
-
Should Beta-Blockers Remain First Choice in the Treatment of Primary Hypertension?; Obstructive Sleep Apnea as a Risk Factor for Stroke and Death; Cholinesterase Inhibitors for Alzheimers Disease
-
The majority of chronic stable coronary artery disease patients given 75 mg of EC aspirin daily have adequate inhibition of COX, but younger, heavier, and post MI patients may not.
-
Patients in an internal medicine outpatient clinic overwhelmingly preferred both male and female doctors in professional attire with a white coat, and were more willing to share their personal history with them.
-
The ECG in the Figure was obtained from a 77-year-old. woman with a history of "heart problems." What can (and can not) be said about this tracing?
-
-
Following a priority review, the FDA has approved deferasirox, the first oral iron chelator for the treatment of chronic iron overload due to transfusions. It will be marketed by Novartis Pharmaceuticals as Exjade®.
-
Patients who receive extended anticoagulation are protected from recurrent VTE while receiving long-term therapy. The clinical benefit is maintained after anticoagulation is discontinued, but the magnitude of the benefit is less pronounced.